Summer 2016 APUA Highlights


  • APUA attends ASM Microbe 2016 annual meeting in Boston
  • APUA receives Allergan award
  • APUA attends Boston BAARN meeting
  • APUA joins FOAR program


  • APUA - Australia


  • Resistance to "last resort" antibiotic is now widespread
  • Travelers acquire antibiotic resistance genes in two days
  • Medicare/Medicaid proposes antimicrobial stewardship rule for U.S. hospitals
  • New studies report antibiotic over-prescription rates in U.S.; falling prescriptions in England and the EU
  • New treatment for multi-drug resistant TB is shorter and cuts costs
  • Concerns arise over 2016 Olympic water quality
  • Poverty breeds antimicrobial resistance
  • Fast food companies urged to curb antibiotic abuse
  • New diagnostic differentiates staph strains
  • Novel innovations offer promise in infection control
  • Harvard chemists use novel platform to create new antibiotics
  • Longitude Prize launches new animation/gam


Smile! Your purchases can mean donations to APUA  


The Faces of Antibiotic Resistance (FOAR) Project

The Alliance for the Prudent Use of Antibiotics (APUA) is part of the U.S. Stakeholder Forum on Antimicrobial Resistance (S-FAR). As part of a joint effort with other S-FAR members, we are seeking patients or family members who have experienced a resistant infection, such as MRSA, CRE, etc. who are willing to share their story.  These stories are critical to help us demonstrate to policymakers the human cost of and urgent need for efforts to combat antimicrobial resistance to protect patients and public health.
Antibiotic resistant bacteria are responsible for at least 23,000 deaths and at least 2 million infections each year, and cost the healthcare system approximately $20 billion.  They also complicate many areas of medicine, including the care of preterm infants, chemotherapy, organ and bone marrow transplants, and other surgeries. 
With APUA’s help, S-FAR is planning to publish a collection of stories by people and families directly impacted by an antibiotic resistant infection.  If you, or one of your loved ones, patients, colleagues, etc., has suffered from an antimicrobial resistant infection and you or they are willing to share your story for this effort, please contact us at by July 31st. We would be happy to work with you to put the story together.  Each person telling their story will be given final approval rights before publication.
Thank you for considering this important request.
APUA Staff

APUA Newsletter Vol. 34. No. 1
"Perspectives on Preserving and Expanding Antimicrobial Options"


APUA Voices Support for Global Industry Declaration Tackling Antimicrobial Resistance
The Alliance for the Prudent Use of Antibiotics (APUA) applauds the global pharmaceutical, biotechnology and diagnostics industry declaration on combating antimicrobial resistance.

“Marking a major step in the global battle fighting the problems of antimicrobial resistance, the statement sets out for the first time how governments and industry need to work together to support sustained investment in the new products needed to beat the challenges of rising drug resistance,” said Dr. Stuart B. Levy, CEO of the Alliance for the Prudent Use of Antibiotics. 

Launched at the World Economic Forum in Davos, Switzerland, this declaration formally cites the encouraging news of more than 85 international companies and nine industry associations across 18 countriesworking together to take collective action to address the resistance problem.


The Alliance for the Prudent Use of Antibiotics is pleased to honor Kevin Outterson, J.D., LL.M., professor at the Boston University School of Law and Boston University School of Public Health, as the recipient of our 2015 Leadership Award.

Professor Outterson, the N. Pike Scholar in Health and Disability Law and co-director of BU's health law program, is the author of groundbreaking models to address the economic challenge of developing new antibiotics. Together with his scholarship and testimony before the United States Congress, he elevates the issues of antimicrobial resistance to a new level, catalyzing access to effective treatment of bacterial infections for all.

"We recognize Professor Outterson as a thought leader in the worldwide effort to contain antibiotic resistance," said APUA President Stuart B. Levy. "His intellectual commitment to the economic realities of developing new drugs that affect the global aspects and consequences of antibacterial resistance alter our thinking about answers to these complex problems."

Our warmest congratulations to Professor Outterson.

In case you missed it, our latest webinar is now available for streaming.
Click the video below





Antibiotics are humanity's key defense against disease-causing microbes. The growing prevalence of antibiotic resistance threatens a future where these drugs can no longer cure infections and killer epidemics run rampant. The Alliance for the Prudent Use of Antibiotics (APUA) has been the leading global non-governmental organization fighting to preserve the effectiveness of antimicrobial drugs since 1981. With affiliated chapters in over 66 developed and developing countries, we conduct research, education and advocacy programs to control antimicrobial resistance and ensure access to effective antibiotics for current and future generations. For more information on antibiotic resistance research, visit our partner lab at the Center for Adaptation Genetics and Drug Resistance.

Antibiotic Resistance
in the News

WHO Worldwide Country Situational Analysis: Response to Antimicrobial Resistance

The National Action Plan for Combating Antibiotic-Resistant Bacteria, 2015

2014 PCAST Report on 
Combating Antimicrobial Resistance






Public Health AdvocacyGlobal Research and Survellience

Consumer and Practioner ResourcesAPUA Chapters

"Antibiotics are uniquely societal drugs because individual use affects others in the community and environment.  Better stewardship, incentives, and establishment of a special regulatory category will improve how they are used, marketed, and developed through incentives to industry."

Stuart B. Levy, M.D.
President of APUA, professor at Tufts University School of Medicine

From the IOM 25th Anniversary Symposium (1996) and The Antibiotic Paradox (2002)

2014 Alliance for the Prudent Use of Antibiotics | 136 Harrison Ave, M&V Suite 811, Boston, MA, 02111 | Tel 617.636.0966 | apua@tufts.eduHome | Search | Contact Us